Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (7,463,259)	$ (11,168,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	375,334	700,276
Accretion of discount on NuvoGen obligation	(6,149)	(6,656)
Provision for excess inventory	5,507	1,672
Amortization of QNAH Convertible Note issuance costs		6,505
Amortization of MidCap Credit Facility discount and issuance costs		101,482
Amortization of SVB Term Loan discount and issuance costs	234,927	3,389
Stock-based compensation expense	677,194	776,793
Employee stock purchase plan expense	26,231	10,758
Non-cash operating lease expense	254,584	306,230
Accrued interest on available-for-sale securities investments	(10,530)	(98,092)
Stock compensation expense in connection with LP Purchase Agreement		205,538
Gain on forgiveness of PPP Loan	(1,735,792)
Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note		522,394
Loss on abandonment and disposal of assets, net	178,925	49,226
Changes in operating assets and liabilities:
Accounts receivable	(114,735)	2,152,714
Inventory	(831,511)	(120,575)
Prepaid expenses and other	(573,569)	171,774
Deferred offering costs		140,320
Accounts payable	443,816	(659,736)
Accrued liabilities	(117,926)	(1,047,223)
Contract liabilities	21,241	(53,284)
Operating lease liabilities	(266,464)	(378,840)
Net cash used in operating activities	(8,902,176)	(8,383,784)
Investing activities
Purchase of property and equipment	(241,474)	(322,372)
Maturities of available-for-sale securities	6,300,000	17,950,000
Purchase of available-for-sale securities	(16,173,223)	(4,272,298)
Net cash (used in) provided by investing activities	(10,114,697)	13,355,330
Financing activities
Proceeds from issuance of SVB Term Loan		10,000,000
Payment of SVB Term loan issuance costs		(45,934)
Proceeds from ATM Offering, net of commissions of $0.3 million	10,665,819	3,830,970
Proceeds from PPP Loan		1,717,000
Proceeds from Series A convertible preferred stock in private placement		562,955
Payments on NuvoGen obligation	(254,979)	(421,525)
Proceeds from exercise of pre-funded warrants		31,768
Proceeds from shares purchased under stock purchase plans	53,437	25,133
Payments on financing leases	(12,694)	(22,845)
Proceeds from exercise of stock options	326
Taxes paid for net share settlement of restricted stock awards	(1,892)	(9,160)
Payments on 2021 and 2020 Insurance Notes	(247,047)	(80,710)
Net cash provided by financing activities	10,202,970	5,149,029
Effect of exchange rates on cash	(7,464)	3,805
Decrease (increase) in cash, cash equivalents and restricted cash	(8,821,367)	10,124,380
Cash, cash equivalents and restricted cash at beginning of period	22,397,812	10,889,995
Cash, cash equivalents and restricted cash at end of period	13,576,445	21,014,375
Supplemental disclosure of noncash investing and financing activities
Fixed asset purchases payable and accrued at period end	41,864
Issuance of Series A convertible preferred stock in exchange for outstanding common stock		2,424,900
Issuance of common stock upon conversion of Series A convertible preferred stock		1,622,500
Issuance of common stock from cashless exercise of pre-funded warrants	145
Operating lease right-of-use assets obtained in exchange for operating lease liabilities		21,078
SVB Term Loan costs payable and accrued at period end		60,710
2021 and 2020 Insurance Notes issued for insurance premiums	746,360	735,195
Gain on forgiveness of PPP Loan	1,735,792
Supplemental cash flow information
Cash paid for interest	296,835	602,200
Cash paid for taxes	$ 12,665	6,581
QNAH Convertible Note
Financing activities
Payments for extinguishment of debt		(3,000,000)
MidCap Credit Facility
Financing activities
Payments for extinguishment of debt		$ (7,438,623)